Unilever licences Arzeda Inc.‘s enzyme technology

According to an analysis from Nova Institute (Cologne), production of chemicals including laundry products 85% (or 450 millon tonnes annually) of the...

Yet another blow to Merck’s cancer hopeful

Merck KGaA announced it has decided to discontinue the Phase II INTR@PID BTC 055 study evaluating bintrafusp alfa with gemcitabine plus cisplatin in...

Rheincell set to be acquired by Catalent

Under the agreement, Catalent will acquire  RheinCell Therapeutics GmbH, a developer and manufacturer of GMP-grade human induced pluripotent...

Bayer takes over Vividion

The acquisition strengthens Bayer's oncology and immunology pipeline and secures a revolutionary screening technology for small molecule drugs that...

ERS Genomics and Cellular Engineering Technologies collaborating

Under the agreement, Cellular Engineering Technologies licences the rights from Dublin-based ERS Genomics Ltd. to develop, manufacture and...

Boehringer walks away from CureVac deal

CureVac announced the termination of the 2014 programme BI1361849 in its financial report. Seven years ago, CureVac had received €35m upfront, with...

Owlstone: US$59m for breath biopsy development

Cambridge-based breath biopsy specialist Owlstone Medical has closed its Series D financing round with US$59m, exceeding its initial target of...